Status:
COMPLETED
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Small Cell Lung Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive ...
Eligibility Criteria
Inclusion
- Histologically or cytologically proven Small Cell Lung Cancer (SCLC)
- WHO performance status : 0, 1
Exclusion
- No previous radiotherapy is allowed except on bone metastases when newly diagnosed. Radiotherapy is not allowed for vena cava syndrome, a stent is recommended ;
- No prior surgery on the primary tumor except for palliative purpose (stent for vena cava syndrome).
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
485 Patients enrolled
Trial Details
Trial ID
NCT00143455
Start Date
June 1 2002
End Date
December 1 2008
Last Update
February 18 2010
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Wels, Austria, A-4600
2
Pfizer Investigational Site
Ghent, Belgium, 9000
3
Pfizer Investigational Site
Leuven, Belgium, 3000
4
Pfizer Investigational Site
Liège, Belgium, 4000